AstraZeneca will buy the stake via around 6.26 million new shares
British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 per cent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.
AstraZeneca will buy the stake via around 6.26 million new shares being issued to it at a price of 10 euros per share, the two companies said recently.
“Our expanded collaboration with Innate Pharma enables us to further strengthen our leadership in immuno-oncology, and to explore the potential of next generation immuno-oncology pathways, together with the world-class scientific team of Innate,” said AstraZeneca Chief Executive Pascal Soriot.
- Advertisement -
Comments are closed.